Sunday, April 26, 2015 9:38:43 AM
You see: it doesn't matter if JB is in jail or out.
........doesn't matter if BORK enlists the help of qualified
professionals to advance KRYRON.
........doesn't matter if BORK could acquire the "magic dust"
for free (no cost).
....... doesn't matter if KRYRON is the real deal
....... doesn't matter if BORK has a fail safe business plan.
....... doesn'e even matter if BORK had $100million in free capital.
....... doesn'e matter if the KRYRON patents were rock solid.
If BORK had all the above, it will still spiral down into Banckruptcy. And that is because John M. Bourque has no inclination
to work hard and play by the rules. His business plan to monetize KRYRON (for himself and a few others) has already been established
and been successful for himself and a few others. Now what you are watching is a repeat performance of the exact same business plan
he put in place before.
Sad thing is ... at this point there is nothing you or I can do
to stop JB from doing it all over again. Probably at this point the only thing that can stop JB are our good buds at the IRS. And that will happen only because there are probably a few high ranking political folks that dumped a ton of money into BORK
and lost it all and they are pissed.
The only mistake JB made in his business plan was the wide net he cast to bring in investors to buy BORK stock in order to drive up the share price also snarred some highly connected political people who can actually "pull the trigger" and cause the FEDS to become interested.
I wouldn't get too excited about buying in now hoping to get
a quick hit from a short burst in the stock price as the hammer could drop at any time. I've already dumped all my shares and got a penny for each share while having an average cost of $1.50 per share. That is as close as you can get to a total loss and I would bet that would bring a smile to JB's face.
THink about it and have a great weekend folks. If you don't believe this ... then you are just fresh meat for JB
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM